Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01623869 · ClinicalTrials.gov registry record · Phase 2
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01623869: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01623869 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01623869, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This phase II trial studies how well trebananib works in treating patients with advanced angiosarcoma that cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.
Primary Outcome
Response and progression will be evaluated using the international RECIST guidelines (v1.1). Patients are evaluated every 8 weeks for disease status, with a subsequent 4 week assessment required to confirm a response. Complete Response (CR) - All of the following must be true: 1. Disappearance of all target and non-target lesions, 2. Each target lesion and non-target lymph node must have reduction in short axis to \<1.0 cm. Partial Response (PR): 1. At least a 30% decrease from the baseline
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Trebananib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT01623869 record still lists
NCT01623869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01623869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01623869 about?
NCT01623869 is a clinical study titled "Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery". This phase II trial studies how well trebananib works in treating patients with advanced angiosarcoma that cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.
What is the current status of trial NCT01623869?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-07. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01623869?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trebananib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01623869?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01623869's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia